The Governors of the University of Alberta

Other

The Secretary of State for Environment, Food and Rural Affairs

Theracarb, Inc.

Mcgill University

Glycomed, Inc.

Pence, Inc.

Zymetx, Inc.

David R Bundle

Pavel Kitov

Glen D Armstrong

Om P Srivastava

Minghui Du

John McGiven

Laurence Howells

Geeta Srivastava

Ole Hindsgaul

Randy J Read

Vijaya Ganesh Narayanaswamy

Hong Ling

Julie Guiard

Robert S Hodges

Randall Thomas Irvin

Kevin R Holme

Jim E Cutler

Avraham Liav

Roman Szweda

R Bruce Lennox

Susmita Sarkar

H Rizk Hanna

Lucy Duncombe

Satadru Sekhar Mandal

Ole Hingsgaul

Mark Nitz

Craig Railton

Kenneth Kai-Sing Ng

Frank W Barresi

Jason Gay Shuen Ho

There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose, each pair of units joined by a C-Cor a C-Clink, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal NI against infection by aorganism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-antibody.

Polysaccharide and methods

There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose and comprising at least one -(1-3)- link between adjacent 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from &#x2014;CHOH, &#x2014;H or an alkyl group having at least one C atom, the oligosaccharide being covalently linked to a non-saccharide molecule or to a surface.

Oligosaccharide conjugates and methods of use

There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose and comprising at least one -(1-3)-link between adjacent 4,6-dideoxy-4-acylamido-&#x3b1;-pyranose units, in which the carbon at position 5 in the pyranose is linked to an R group, where R is independently selected from &#x2014;CHOH, &#x2014;H or an alkyl group having at least one C atom, the oligosaccharide being covalently linked to a non-saccharide molecule or to a surface.

The present invention provides methods of making and using immunogenic oligosaccharide compositions comprising native O-linked and S-linked oligosaccharides coupled to a protein carrier, wherein the resultant conjugate elicits a protectively immunogenic response. These compositions may be useful in vaccines against pathogenicspecies.

[object Object]

Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are useful for treating amyloidosis and diseases associated with amyloidosis, for example Alzheimer&supl;s disease and maturity onset diabetes mellitus.

Multivalent inhibitors of serum amyloid P component

The present invention provides improved method of preparing a 4-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) and a 7-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in the selective detection of various influenza viruses and parainfluenza viruses. The ketosides are substrates that are selectively cleaved by a neuraminidase on the virus to be detected, but not by neuraminidases found on other viruses or on bacteria, or on the cells of the host. The syntheses are efficient and provide large quantities of the ketosides for commercial development. The synthesis includes a step of alkylating the 4- or 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by processes that include contacting the derivative with a composition comprising an alkyl halide to form a 4- or a 7-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac. The syntheses alternatively include protecting the 8- and 9-hydroxyl groups of an alkyl ester alkyl ketoside derivative of Neu5Ac by forming an 8,9-ketal or an 8,9-epoxide protected alkyl ester alkyl ketoside derivative of Neu5Ac.

Syntheses of 4-alkyl chromogenic glycosides and 7-alkyl chromogenic glycosides of N-acetylneuraminic acids

Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from,, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic,(EPEC) and enterotoxigenic,(ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves. In one embodiment, the compounds, when administered in a timely fashion to a patient suffering from enteric,infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

Treatment of bacterial infections

The present invention provides an improved method of preparing a 4,7-di-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in detecting influenza virus types A and B. The ketosides are substrates that are selectively cleaved by a neuraminidase on influenza virus, but not be neuraminidases found on other viruses or on bacteria. The synthesis is efficient and provides large quantities of the ketoside for commercial development. The synthesis includes a step of alkylating the 4- and 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by a process that comprises contacting the derivative with a composition comprising an alkyl halide to form a 4,7-di-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac. The synthesis alternatively includes protecting the 8- and 9-hydroxyl groups of an alkyl ester alkyl ketoside derivative of Neu5Ac by forming an 8,9-epoxide protected alkyl ester alkyl ketoside derivative of Neu5Ac.

Synthesis of 4,7-dialkyl chromogenic glycosides of N-acetylneuraminic acids

Compounds which bind to shiga-like toxins (SLT) associated with enteric E. coli infection, compositions including the compounds, methods for the neutralization of (SLT) in a patient, and methods for the diagnosis of enteric E. coli infection are disclosed. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to two or three di- or tri-saccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the di- and tri-saccharides is responsible for the increased binding affinity of the compounds relative to the di- and tri-saccharides themselves. The compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

Treatment of bacterial dysentery

A biosensor apparatus for detecting a binding event between a ligand and receptor. The apparatus includes an electrode substrate coated with a high-dielectric hydrocarbon-chain monolayer, and having ligands attached to the exposed monolayer surface. Binding of a receptor to the monolayer-bound ligand, and the resultant perturbation of the monolayer structure, causes ion-mediated electron flow across the monolayer. In one embodiment, the monolayers have a coil--coil heterodimer embedded therein, one subunit of which is attached to the substrate, and the second of which carries the ligand at the monolayer surface.

Biosensor device and method

Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.

Oligosaccharide glycosides having mammalian immunosuppresive and

Growing community of inventors

Edmonton, Canada

David R Bundle